BOULDER, Colo., April 30, 2019 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) will report financial results for the
third quarter of fiscal 2019 and hold a conference call to discuss
those results on Tuesday, May 7, 2019
at 9:00 am ET.
|
Date:
|
Tuesday, May 7,
2019
|
|
Time:
|
9:00 a.m. Eastern
Time
|
|
Toll-Free:
|
(844)
464-3927
|
|
Toll:
|
(765)
507-2598
|
|
Pass
Code:
|
3638409
|
|
|
Webcast, including
Replay and Conference Call Slides:
|
|
https://edge.media-server.com/m6/p/bt2tyqof
|
About Array BioPharma
Array BioPharma Inc. is a fully
integrated biopharmaceutical company focused on the discovery,
development and commercialization of transformative and
well-tolerated targeted small molecule drugs to treat patients
afflicted with cancer and other high-burden diseases. Array markets
BRAFTOVI® (encorafenib) capsules in combination with
MEKTOVI® (binimetinib) tablets for the treatment of
patients with unresectable or metastatic melanoma with a
BRAFV600E or BRAFV600K mutation
in the United States and with
partners in other major worldwide markets. Array's lead clinical
programs, encorafenib and binimetinib, are being investigated in
over 30 clinical trials across a number of solid tumor indications,
including a Phase 3 trial in BRAF-mutant metastatic
colorectal cancer. Array's pipeline includes several additional
programs being advanced by Array or current license-holders,
including the following programs currently in registration trials:
selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with
Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib
(partnered with Seattle Genetics) and ARRY-797.
Vitrakvi® (larotrectinib, partnered with Loxo
Oncology) is approved in the United
States and Ganovo® (danoprevir, partnered with
Roche) is approved in China. For
more information on Array, please visit www.arraybiopharma.com or
follow @arraybiopharma on Twitter and LinkedIn.
CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2019-on-may-7-2019-300840936.html
SOURCE Array BioPharma Inc.